Why the ResMed (ASX:RMD) share price just hit an all-time high

A confluence of factors are pushing its share price higher.

| More on:
four excited doctors with their hands in the air

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc.(ASX: RMD) share price is breaking new records.

At the time of writing, shares in the healthcare company are trading for $35.28 – up 0.54%. At one point, shares reached an intraday and all-time high of $35.44.

The S&P/ASX 200 Index (ASX: XJO) is also having a record day. Presently, the benchmark index is 0.05% higher but reached a high of 7,417.6 points. While the influence of the general market on the ResMed share price could be having an effect, there may be more to the story.

Let's take a closer look.

Healthcare shares are looking fit

Throughout July, ASX healthcare shares, like ResMed, have been surging. Just in the last month, the ResMed share price has jumped 8.1%, Sonic Healthcare Limited (ASX: SHL) improved 8.2% and CSL Limited (ASX: CSL) shares are up 1.5%.

With COVID back in the spotlight, as the delta variant causes a sharp increase in cases across the world, healthcare shares – including ResMed – may be the few to benefit from this strain of the virus.

Experts too have had nothing but positive words to say about the ResMed share price in recent days.

Analysts at Macquarie Group, for example, say ResMed is a growth share for investors to buy right now. Randal Jenneke, head of Australian equities at T Rowe Price Group, says ResMed is a "quality" share for investors.

Jenneke previously said

Over more than two decades of data for the Australian market, high quality had outperformed low quality by 6.7% per annum.

… [quality shares like ResMed are] poised to outperform over the coming year.

As the ResMed share price has just hit a 52-week high, this advice is being borne out – at least for the time being.

Another factor potentially helping ResMed shares – the falling Aussie dollar.

Experts are tipping it to fall below 70 cents against the greenback. For ASX listed companies that predominately do business in the US, this could be a windfall.

ResMed is one of those companies that predominantly trade in the US. In fact, it is a dual listed company with shares on the New York Stock Exchange.

ResMed share price snapshot

Over the past 12 months, the ResMed share price has increased 23.1%. Year-to-date it is up an even greater 28.3%.

ResMed has a market capitalisation of around $51 billion.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has recommended ResMed Inc. and Sonic Healthcare Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Lab technician analyses a sample in a laboratory for a clinical trial
Earnings Results

Monash IVF share price plunges 18% on lower FY26 profit guidance and no dividend

Revenue and EBITDA increased in FY25 but the outlook is gloomy and no final dividend will be paid.

Read more »

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

Why is everyone talking about CSL shares?

CSL suffered a ‘brutal selloff’ this week.

Read more »

A woman presenting company news to investors looks back at the camera and smiles.
Healthcare Shares

Why this ASX 200 stock could be a bargain buy after crashing 13%

Bell Potter thinks that a buying opportunity could have opened up for investors.

Read more »

A man flies into the sky over a city building-scape with a rocket jet pack sketched onto his back representing the Imugene share price skyrocketing today
Healthcare Shares

A $115 million growth opportunity!? Is this ASX 200 stock about to skyrocket?

The company's share price has jumped 141.67% over the past 12 months.

Read more »

A financial expert or broker looks worried as he checks out a graph showing market volatility.
Healthcare Shares

Is the CSL share price dirt cheap after crashing this week?

Is this beaten down biotech cheap? Let's find out.

Read more »

A man in a business suit rides a graphic image of an arrow that is rebounding on a graph.
Broker Notes

Why Macquarie says the HUGE sell-off in CSL shares is way overdone

Macquarie forecasts a big rebound is coming for CSL shares. But why?

Read more »

A sole trekker climbs a steep snowy mountain.
Healthcare Shares

This ASX healthcare stock could be a buy low bargain

After a rough 12 months, is this a buy low target?

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Broker Notes

Does Macquarie rate Pro Medicus shares a buy after they surged again on FY25 results?

Macquarie delivers its verdict on the 12-month outlook for Pro Medicus shares.

Read more »